1. Home
  2. DSP vs SRZN Comparison

DSP vs SRZN Comparison

Compare DSP & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.65

Market Cap

213.3M

Sector

Technology

ML Signal

HOLD

Logo Surrozen Inc.

SRZN

Surrozen Inc.

HOLD

Current Price

$25.91

Market Cap

210.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
SRZN
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.3M
210.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DSP
SRZN
Price
$11.65
$25.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
2
Target Price
$18.11
$36.00
AVG Volume (30 Days)
218.4K
68.3K
Earning Date
03-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
N/A
EPS
0.36
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$16.52
N/A
Revenue Next Year
$16.62
N/A
P/E Ratio
$32.92
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$7.11
52 Week High
$16.25
$29.60

Technical Indicators

Market Signals
Indicator
DSP
SRZN
Relative Strength Index (RSI) 58.72 51.40
Support Level $11.09 $23.63
Resistance Level $12.63 $28.78
Average True Range (ATR) 0.86 2.37
MACD 0.20 -0.40
Stochastic Oscillator 63.54 40.79

Price Performance

Historical Comparison
DSP
SRZN

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About SRZN Surrozen Inc.

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Share on Social Networks: